Artificial Organ And Bionics Market Size, Share & Trends Analysis Report By Product (Artificial Heart, Liver, Kidney Pancreas, Exoskeleton, Cochlear Implant), By Technology (Mechanical, Electronic), By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global artificial organ and bionics market size was valued at USD 25.3 billion in 2021 and is projected to expand at a compound annual growth rate (CAGR) of 9.3% from 2022 to 2030. The key drivers of the market for artificial organs and bionics are the increasing number of transplants, coupled with the rising number of people waiting for donors. According to the Human Resource and Services Administration (HRSA), there are more than 106,108 people on the national waiting list in 2022 in the U.S. The HRSA reports that every nine minutes, a person is added to the transplant waiting list in the U.S., resulting in greater demand for artificial medical devices.

The COVID-19 pandemic arose as an unprecedented health crisis, adversely affecting the artificial organ and bionics market. The coronavirus pandemic has affected millions of people worldwide, resulting in significant deaths, disease burden, and financial instability. The healthcare system and facilities were under extreme strain as a result of the massive patient influx.

The delay in other medical procedures was caused by prioritizing patients afflicted by COVID-19, affecting the market growth. This delay impacted many elective procedures, further reducing product adoption. Orthopedic bionic devices are widely used after amputation surgery to help partially or completely restore movement in limbs or arms. Although, the decreased number of amputation procedures during the epidemic hampered industry growth by lowering device acceptance rates. However, due to the ease of lockdowns and several restrictions, the market is expected to flourish during the forecast period.

Primary factors for organ failure are loss of blood, drug abuse, serious trauma, and other acute diseases. Furthermore, lifestyle disorders such as unhealthy dietary habits, smoking, excessive alcohol consumption, and lack of exercise negatively impact organ function. In addition, development in healthcare facilities and the availability of advanced artificial support systems are expected to boost the demand for artificial organs and bionics.

The rising global geriatric population is primarily creating demand for organ implants. The number of people aged over 65 years of age receiving and seeking organ transplants is on the rise. Demand for artificial devices in the older population is highest, as they are more susceptible to post-transplant malignancies. According to the HRSA, in 2021, there were 8,895 (as of now, 3,114 in April 2022) organ transplant procedures performed on the population aged over 65 in the U.S. Thus, increasing life expectancy and rising demand for organ donors are boosting the demand for artificial devices.

Advancements in the field of 3D bioprinting have proven to be crucial in organ transplanting as it is used for developing artificial organs. 3D bioprinting is relatively popular since it minimizes the risk of organ rejection. Furthermore, artificial intelligence is poised to transform the global trends for artificial devices. Currently, many countries are focusing on a tool that provides a customized assessment of organ and donor suitability. This tool would be very helpful in making effective decisions about organ retrieval and will also help patients in deciding if they should accept donor organs or wait for better options.

Product Insights

Artificial organs dominated the market, with a share of over 70.9% in 2021. Demand for kidney, heart, lungs, and liver transplants is contributing to the growth of the segment. The average median waiting time to transplant a kidney in the U.S. is 5 years. Many factors are considered while on the waiting list, such as body size, blood type, distance from a donor, and severity of illness. Thus, the challenge of fulfilling unmet demand has compelled the manufacturers to develop bio-lungs, artificial pancreas, and wearable artificial kidneys.

The artificial bionics segment is projected to witness the fastest CAGR during the forecast period. Primary factors contributing to the segment's growth are the increasing demand for cochlear implants, vision, exoskeleton, limbs, and brain bionics. Furthermore, favorable reimbursement policies and fast-track FDA approval for implants are strengthening the growth of the market for artificial organs and bionics. For instance, in January 2022, the Cochlear Nucleus Implants of Cochlear Limited received clearance from the U.S. Food and Drug Administration to treat unilateral hearing loss and single-sided deafness.

Technology Insights

Mechanical bionics dominated the market with a share of 67.1% in 2021. This is primarily attributed to the rising incidence of organ failure and the low cost of mechanical bionics. A mechanical artificial heart valve lasts much longer as compared to the other options, creating a robust demand. Other factors contributing to the growth are speedy FDA approvals and reimbursement policies. For instance, in September 2021, the FDA approved Abbott's Portico with FlexNav TAVR system to treat individuals with symptomatic and aortic stenosis who may be at high or very high risk for open-heart surgery.

The electronic bionics segment is expected to register the highest growth rate in the artificial organs and bionics market during the forecast period. According to Bionics Queensland, approximately 1.0 billion people are living with a physical disability, and 190.0 million adults have primary functional difficulty. In most developing countries, the logistical and financial barriers remain high. The only option for many who are disabled is to obtain prosthetics such as artificial hands, arms, and legs.

These prosthetics are battery and electronic systems that are myoelectric-controlled and can create nerve movement through sensors. These sensory electric technologies enable mobility in artificial organs. Machine learning, smart wearables, and element modeling are used to achieve mobility. In addition, an increasing number of road accidents, the rising prevalence of amputees, and individuals born without limbs are expected to create a demand for electronic bionics.

Regional Insights

North America dominated the market in 2021 with a share of 45.4% and is expected to continue its dominance throughout the forecast period. The reason for this growth is the increase in transplant surgeries and the need for artificial organs due to the high incidence of organ failure. Furthermore, the presence of well-developed healthcare facilities and local presence of many large biotechnology and medical devices companies, such as Zimmer Biomet, Arthrex, Inc., Medtronic, Novartis AG, and Stryker, contribute to its dominance.

For instance, on 10 March 2022, Zimmer Biomet Holdings, Inc. released WalkAI, an evolving AI design that recognizes patients1 who are expected to have a lesser gait speed outcome ninety days after hip or knee surgical intervention. WalkAI augments ZBEdge, a suite of integrated smart, robotic technologies digitally designed to offer transformative data-powered clinical insights to boost patient outcomes, with strong predictive analytic capabilities.

The number of donors in the U.S. has increased significantly in the last 5 years. According to the U.S. Department of Health and Human Services, there was a 27.7% increase in the number of organ donors from 2015 to 2019. The growing demand for kidney transplantation is one of the major drivers of the market for artificial organs and bionics. Kidney transplantation witnessed an exponential growth from 16,186 transplants in 2011 to 23,401 transplants in 2019 and 24,670 in 2021.

In the Asia Pacific, the market is expected to grow at the fastest rate during the forecast period, owing to emerging economies like Japan, China, and India. These countries have a large population base with a high incidence of chronic diseases. An increase in the number of chronic diseases that lead to organ failure is expected to boost artificial organ and bionics device growth.

For instance, in February 2022, Warburg Pincus invested USD 210 in Micro Life Sciences Pvt Ltd (parent organization of Meril group of companies). This investment will promote domestic medical devices at a high level of legitimacy in the global context, allowing them to expand their overseas footprint, attract international talent, and scale-up clinical research programs.

The countries are technologically advanced and offer various advanced surgical procedures with booming medical tourism. The low cost of surgical procedures in the region allows many patients to visit for medical reasons. Thus, an increase in the number of chronic diseases leading to organ failure and a rise in medical tourism has contributed significantly to the growth of the market in the region.

Key Companies And Market share Insights

The market for artificial organs and bionics is highly fragmented with the presence of many large, small, and medium-scale vendors. The leading players in the industry are Syncardia, Berlin Heart Gmbh, Ekso Bionics, and Edwards Lifesciences Corporation. These players are engaged in the development of innovative products and regional expansion to gain maximum revenue share in the industry. Mergers and acquisitions support prominent leaders in expanding their existing product portfolio and increasing their geographical footprints. For instance, in March 2022, Edwards Lifesciences confirmed that the MITRIS RESILIA valve, it’s a tissue valve replacement specially developed for the heart's mitral position, has obtained FDA clearance.

Rising regulatory approvals for artificial organs and other materials along with the development of innovative products, such as 3D bioprinting have led to high demand for transplant products. This 3D bioprinting can be used to regenerate tissues and organs. For instance, For example, Readily3D SA, a Swiss bioprinting organization, obtained USD 600,000 from the EU in May 2021 to create a living scale model of the pancreas through its Tomolite 3D bioprinting method. Some of the prominent companies operating in the global artificial organ and bionics market are:

• Zimmer Biomet

• Medtronic

• Abbott

• ABIOMED, INC

• Berlin Heart Gmbh

• Biomet, Inc

• Boston Scientific Corporation

• Edward Lifesciences Corporation

• Ekso Bionics

• Heartware International, Inc

• Iwalk, Inc.

• Jarvik Heart, Inc

• SynCardia Systems, LLC.

Artificial Organ And Bionics Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global artificial organ and bionics market report based on product, technology, and region:

• Product Outlook (Revenue, USD Million, 2017 - 2030)

  • Artificial Organs

    • Kidney

    • Heart

    • Lungs

    • Liver

    • Pancreas

  • Artificial Bionics

    • Cochlear implant

    • Exoskeleton

    • Bionic limbs

    • Vision bionics

    • Brain bionics

• Technology Outlook (Revenue, USD Million, 2017 - 2030)

  • Mechanical bionics

  • Electronic bionics

• Regional Outlook (Revenue, USD Million, 2017 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE